Patents by Inventor Matthew Duncton

Matthew Duncton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220204486
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R1, R2, R2a, R3, and R3a are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: June 30, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220144819
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R1, R2, R2a, R3, R3a, R3b, and subscript n are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: May 12, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • DIRECT AMPK ACTIVATORS
    Publication number: 20220098175
    Abstract: Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 31, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Simon Shaw, Xiang Xu, Sarkiz Issakani, Rajinder Singh, Yasumichi Hitoshi, Matthew Duncton, Nan Lin
  • Nrf2 activating compounds and uses thereof
    Patent number: 11279686
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: March 22, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Rajinder Singh
  • PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220033399
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 3, 2022
    Inventors: John Kincaid, Matthew Duncton
  • CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220009887
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 13, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20210380601
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I): where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Application
    Filed: April 20, 2021
    Publication date: December 9, 2021
    Inventors: John KINCAID, Matthew DUNCTON
  • Direct AMPK activators
    Patent number: 11174246
    Abstract: Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 16, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Simon Shaw, Xiang Xu, Sarkiz Issakani, Rajinder Singh, Yasumichi Hitoshi, Matthew Duncton, Nan Lin
  • Pyrrolopyridine-aniline compounds for treatment of dermal disorders
    Patent number: 11161845
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Nflection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Fumarate analogs and uses thereof
    Patent number: 11129819
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
  • Fused heteroaromatic-aniline compounds for treatment of dermal disorders
    Patent number: 10988483
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 27, 2021
    Assignee: NFlection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20210078969
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 20, 2020
    Publication date: March 18, 2021
    Inventors: Matthew Duncton, Rajinder Singh
  • Nrf2 activating compounds and uses thereof
    Patent number: 10941135
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: March 9, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Rajinder Singh
  • Nrf2 activating compounds and uses thereof
    Patent number: 10844040
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 24, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Rajinder Singh
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20200339538
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: April 2, 2020
    Publication date: October 29, 2020
    Inventors: Matthew Duncton, Rajinder Singh
  • Protein kinase C inhibitors and uses thereof
    Patent number: 10792282
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 6, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20200216412
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 9, 2020
    Inventors: Matthew Duncton, Rajinder Singh
  • FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20200172550
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Inventors: John Kincaid, Matthew Duncton
  • PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20200165243
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a and R3b are as described herein.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 28, 2020
    Inventors: John Kincaid, Matthew Duncton
  • Fumarate Analogs and Uses Thereof
    Publication number: 20200155531
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 21, 2020
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh